Loading...
XNASCODX
Market cap25mUSD
Jan 17, Last price  
0.80USD
1D
2.53%
1Q
-37.89%
IPO
-85.80%
Name

Co-Diagnostics Inc

Chart & Performance

D1W1MN
XNAS:CODX chart
P/E
—
P/S
3.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
18.64%
Rev. gr., 5y
179.54%
Revenues
7m
-80.09%
010,00007,66239,911214,97474,552,75897,885,60334,218,2096,812,038
Net income
-35m
L+148.15%
-1,048,124-2,043,168-1,928,686-6,959,232-6,271,723-6,069,11342,478,52936,658,564-14,238,249-35,332,865
CFO
-22m
L
-925,228-1,530,371-1,312,267-3,211,401-4,080,036-5,525,09128,165,23541,081,4246,568,737-22,081,865
Earnings
Mar 12, 2025

Profile

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
URL
http://codiagnostics.com/
IPO date
Jul 12, 2017
Employees
145
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
6,812
-80.09%
34,218
-65.04%
Cost of revenue
48,288
44,527
Unusual Expense (Income)
NOPBT
(41,476)
(10,309)
NOPBT Margin
Operating Taxes
(2,778)
(4,609)
Tax Rate
NOPAT
(38,698)
(5,700)
Net income
(35,333)
148.15%
(14,238)
-138.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
(1,364)
(13,731)
BB yield
3.49%
17.31%
Debt
Debt current
1,677
297
Long-term debt
5,143
399
Deferred revenue
Other long-term liabilities
1,407
2,224
Net debt
(52,502)
(81,240)
Cash flow
Cash from operating activities
(22,082)
6,569
CAPEX
(1,365)
(1,428)
Cash from investing activities
15,389
(58,168)
Cash from financing activities
(1,364)
(14,034)
FCF
(34,075)
4,159
Balance
Cash
58,548
81,263
Long term investments
773
673
Excess cash
58,981
80,225
Stockholders' equity
4,781
40,259
Invested Capital
86,469
75,652
ROIC
ROCE
EV
Common stock shares outstanding
29,347
31,479
Price
1.33
-47.22%
2.52
-71.78%
Market cap
39,031
-50.80%
79,327
-70.29%
EV
(13,471)
(1,913)
EBITDA
(40,245)
(9,026)
EV/EBITDA
0.33
0.21
Interest
14,883
Interest/NOPBT